Nasus Pharma Advances Anaphylaxis Treatment Toward Pivotal Trial
Event summary
- Nasus Pharma appointed Brendan O’Grady as CEO effective July 27, 2026.
- NS002 intranasal epinephrine powder showed superior absorption vs. EpiPen® in Phase 2 trials.
- Company raised $15M in private placement, boosting cash to $11.9M as of June 30, 2026.
- Pivotal study for NS002 planned Q4 2026 with topline data expected Q1 2027.
- NS003 ondansetron formulation set for first-in-human PK study in weeks.
The big picture
Nasus Pharma is advancing its intranasal epinephrine treatment (NS002) toward a pivotal trial, aiming to challenge the dominance of injectable anaphylaxis treatments like EpiPen®. The appointment of industry veteran Brendan O’Grady as CEO signals a focus on commercialization as the company prepares for potential regulatory milestones. With $11.9M in cash and a growing pipeline, Nasus Pharma is positioning itself in the competitive intranasal drug delivery space, where rapid absorption and patient-friendly administration are key differentiators.
What we're watching
- Pivotal Trial Timing
- Whether NS002 can maintain its Phase 2 advantages in the upcoming pivotal study.
- Commercial Strategy
- How Nasus Pharma will position NS002 against EpiPen® in a $2B market.
- Cash Runway
- The pace at which the company will need to secure additional funding beyond Q2 2027.